Physician profile
Tracy E Topjun
NPI 1629262977
$4,534.65
in general payments reported to CMS, 2019-2025
41 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $711 · 2022: $314 · 2023: $382 · 2024: $632 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.39 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $378.37 | 2025 | Benlysta, Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $338.60 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $308.68 | 2024-2025 | Saphnelo, Breztri, Airsupra |
| Amgen INC. | $256.55 | 2024-2025 | Otezla, Evenity, Otezla |
| Ucb, INC. | $245.68 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $217.46 | 2024-2025 | |
| Allergan, INC. | $213.68 | 2021-2022 | |
| Pfizer INC. | $205.22 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $96.00 | 2022-2024 | Xtampza |
| Mallinckrodt Hospital Products INC. | $90.50 | 2025 | Acthar |
| Aurinia Pharma U.S., INC. | $71.11 | 2024-2025 | Lupkynis |
| Biohaven Pharmaceutical Holding Company LTD. | $70.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.77 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $63.92 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $62.54 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $56.07 | 2024-2025 | Zepbound, Mounjaro, Taltz |
| Scilex Pharmaceuticals INC. | $47.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.32 | 2025 | Orencia |
| Almatica Pharma LLC | $41.81 | 2021-2022 | |
| Corcept Therapeutics | $41.32 | 2025 | Korlym |
| Novo Nordisk INC | $39.83 | 2025 | Ozempic |
| Kowa Pharmaceuticals America, INC. | $39.34 | 2022-2023 | Seglentis |
| Pacira Therapeutics, INC. | $34.85 | 2021 | |
| Ibsa Pharma INC. | $33.46 | 2021 | |
| Sobi, INC | $29.97 | 2025 | |
| Stryker Corporation | $27.67 | 2021 | |
| Lundbeck LLC | $27.18 | 2023 | Vyepti |
| Spr Therapeutics, INC | $24.75 | 2024 | Sprint Pns System |
| Xeris Pharmaceuticals, INC. | $22.43 | 2025 | Gvoke Hypopen |
| Fresenius Kabi USA, LLC | $16.55 | 2025 | Tyenne |
| Curonix LLC | $15.23 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Kiniksa Pharmaceuticals International, Plc | $15.18 | 2024 | Arcalyst |
| Abbott Laboratories | $14.24 | 2024 | Proclaim |
| Sequel Med Tech, LLC | $14.22 | 2025 | Twiist |
| Redhill Biopharma INC. | $14.01 | 2021 | |
| Merck Sharp & Dohme LLC | $13.93 | 2025 | Gardasil 9, Capvaxive |
| Fidia Pharma USA INC. | $13.63 | 2024 | Triluron, Hyalgan, Hymovis |
| Hikma Pharmaceuticals USA | $12.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $12.44 | 2025 | Opsynvi |
| Nevro Corp. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Topjun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.